The following Life Sciences practice note Produced in partnership with Francesca Blythe of Sidley Austin and William Long of Sidley Austin provides comprehensive and up to date legal information covering:
BREXIT: On 31 January 2020, the UK ceased to be an EU Member State and entered an implementation period, during which it continues to be subject to EU law. During this period, the General Data Protection Regulation applies in the UK and the UK generally continues to be treated as an EU (and EEA) state for many purposes. Any references to EEA or EU states in this Practice Note should therefore be read to also include the UK until the end of the implementation period. As a third country, the UK can no longer participate in the EU’s political institutions, agencies, offices, bodies (except to the limited extent agreed), but it must submit to the continuing jurisdiction of the Court of Justice of the EU during the implementation period. For further guidance on that period, its duration and the data protection laws that are anticipated to apply after the end of it, see Practice Note: Brexit—implications for data protection. For further reading about the impact of Brexit on the Life Sciences, see: Brexit—Life Sciences and News Analysis: Brexit Bulletin—key updates, research tips and resources.
Data, and consequently data protection compliance, is central to conducting clinical research whether in the context of clinical trials, pharmacovigilance activities and/or scientific research more broadly.
As of 25 May 2018, data protection law in the EU is governed by the EU’s
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
This Practice Note provides an introduction to intercreditor agreements and their key provisions. This Practice Note:•explains the purpose of having an intercreditor agreement and when an intercreditor agreement would be used instead of a deed of priority or subordination deed•provides links to
Unlike many other countries, the UK has no unfair competition law. Brand owners seeking to prevent competitors from marketing ‘copycat’ products or using misleading advertising have to rely on a combination of different intellectual property rights. These rights include the common law right to
When defendants are guilty, they have a choice to plead guilty or to put the prosecution to proof. When they plead guilty they may benefit from a reduction in their sentence as a result, see Practice Note: Credit for guilty plea. However, the Sentencing Council's overarching guidelines on reduction
This Practice Note provides guidance on the interpretation and application of the relevant provisions of the CPR. Depending on the court in which your matter is proceeding, you may also need to be mindful of additional provisions—see further below.Note: this Practice Note does not deal with the
0330 161 1234
To view our latest legal guidance content,sign-in to Lexis®PSL or register for a free trial.